A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Merck & Co.

Editor’s Note: This article was updated on a continuous basis for news announced from Wednesday June 20, 2018 date to Friday June 29, 2018.

FDA OKs New Use of Merck & Co.’s Keytruda for Lymphoma
The US Food and Drug Administration (FDA) has approved a new use for Merck & Co.’s Keytruda (pembrolizumab), an anti-programmed death (PD)-1 antibody, for treating adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma, or who have relapsed after two or more prior lines of therapy.

In the US, Keytruda is indicated for treating various cancers, including: metastatic melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin’s lymphoma, urothelial carcinoma, cervical cancer, and gastric cancer.

Source: Merck & Co.